Effect of a DASH-Style Diet on Urinary Risk Factors for Kidney Stone Disease

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jan 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a healthy diet, specifically a DASH-style diet (which emphasizes fruits, vegetables, whole grains, and low-fat dairy), can affect the risk of kidney stone disease. The goal is to see if following this diet for one week can improve factors related to kidney stone formation in people who have had kidney stones before. Participants will be randomly assigned to either follow the DASH diet or a typical Western-style diet, and all meals will be prepared for them by a specialized kitchen.

To be eligible for the trial, participants should be between 19 and 89 years old, live in the Birmingham, AL area, and have a documented history of kidney stones. They must also be willing to collect urine samples for 24 hours and consume the meals provided, without any food allergies to the ingredients used in the study. Notably, individuals with certain medical conditions, such as those on dialysis or who have had a kidney transplant, will not be eligible. This study is important as it aims to set a foundation for future research on how dietary changes can help reduce the risk of kidney stones.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Birmingham, AL area participants of the Coronary Artery Risk Development in Young Adults (CARDIA) study OR patients of the University of Alabama at Birmingham/Kirklin Clinic
• • Self-reported, documented, and/or prior imaging-based diagnosis of kidney stone disease
• • Age 19-89
• • Any sex
• • Any race
• • Able to provide informed consent
• • Willing to perform 24-hour urine collections
• • Willing to consume meals prepared by Bionutrition Unit
• • No food allergies/intolerance to any of the foods in the study menus
• • Willing to stop for 7 days before and during study: Multivitamins and/or Dietary supplements (including calcium and vitamin C)
• Exclusion Criteria:
• • Dialysis
• • Kidney transplant recipient
• • Estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73m2 based on historical laboratory measurements
• • Renal tubular acidosis
• • Current use of acetazolamide, topiramate, or zonisamide
• • Primary hyperparathyroidism or history of parathyroidectomy
• • Hyperthyroidism
• • Sarcoidosis
• • Primary hyperoxaluria
• • Cystinuria
• • Nephrotic syndrome
• • Malabsorptive conditions including inflammatory bowel disease or history of malabsorptive surgery (e.g., Roux-en-Y gastric bypass, small bowel resection)
• • Urinary retention requiring catheterization
• • Urinary diversion
• • Pregnancy
• • Breastfeeding
• • Malignancy treated in the past 12 months other than non-melanoma skin cancer